Abstract

Administration of a rational and safe drug therapy is one of the most challenging issues for healthcare professionals. The frequency of hospitalizations due to the adverse drug reactions in the years 2000 — 2015 was estimated at 6.3 (3.3—11.0 %) for developed countries and 5.5 % (1.1—16.9 %) for developing countries. It is known that alcohol intake is a risk factor for many socially significant diseases, including arterial hypertension, coronary heart disease, chronic heart failure, etc., however, many doctors pay insufficient attention to the fact that many drugs, for example, beta-blockers, antidepressants, bezodisepines, calcium antagonists, can interact with alcohol when consumed simultaneously and, thus, increase the risks of adverse drug reactions. There are 2 main types of interactions between alcohol and drugs: pharmacokinetic (at the stage of absorption, distribution, metabolism and elimination) and pharmacodynamic (at the stage of effects and receptors). For example: the simultaneous intake of alcohol and paracetamol leads to the formation of toxic metabolites due to the induction of cytochrome P450 isoenzymes by alcohol. Another example is decrease in presystemic elimination and stimulation of the metabolism of tricyclic antidepressants; an increase in the elimination of imipramine and desipramine in patients with chronic alcoholism after detoxification therapy, and so on. In this article, the authors analyzed and systematized data from open literature sources in order to inform health care professionals about the possible risks associated with the interaction of alcohol and drugs and various pharmacological groups.

Highlights

  • It is known that alcohol intake is a risk factor for many socially significant diseases, including arterial hypertension, coronary heart disease, chronic heart failure, etc., many doctors pay insufficient attention to the fact that many drugs, for example, beta-blockers, antidepressants, bezodisepines, calcium antagonists, can interact with alcohol when consumed simultaneously and, increase the risks of adverse drug reactions

  • Another example is decrease in presystemic elimination and stimulation of the metabolism of tricyclic antidepressants; an increase in the elimination of imipramine and desipramine in patients with chronic alcoholism after detoxification therapy, and so on

  • The authors analyzed and systematized data from open literature sources in order to inform health care professionals about the possible risks associated with the interaction of alcohol and drugs and various pharmacological groups

Read more

Summary

БЕЗОПАСНОСТЬ ЛЕКАРСТВ

Для цитирования: Сычёв Д.А., Остроумова О.Д., Переверзев А.П., Кочетков А.И., Остроумова Т.М., Эбзеева Е.Ю., Клепикова М.В. Что более 41 % человек пожилого и старческого возраста употребляли алкоголь регулярно (как минимум один раз в неделю), при этом более 20 % из них имели повышенный риск взаимодействия ЛС и алкоголя, т. В другом кросс-секционном популяционном исследовании [29], в которое вошли данные пациентов в возрасте ≥60 лет из Ирландского многолетнего исследования старения The Irish Longitudinal Study on Ageing (TILDA) [29] (n=3815), было выявлено, что 72 % участников данного исследования принимали препараты, которые потенциально могут взаимодействовать с алкоголем (преимущественно ЛС для лечения заболеваний cердечно-сосудистой и ЦНС), при этом 60 % из них сообщили о сопутствующем употреблении алкоголя. Примеры потенциальных взаимодействий различных фармакологических групп ЛС и отдельных ЛС с алкоголем (этанолом), а также их возможные клинические проявления представлены в табл. 1. [21, 31,32,33,34]

Pharmacokinetic and pharmacodynamic interactions of ethanol and drugs
Повышение биодоступности за счёт снижения пресистемной элиминации
Токсическое действие алкоголя
Повышение риска гепатотоксических реакций
Седативные препараты и гипнотики
Необходимость в применении более высоких доз пропофола
Амитриптилин Ацетилсалициловая кислота Абакавир Хлордиазепоксид
Повышение AUC и Cmax
Усиление стимуляции выделения дофамина
Любые антипсихотики
Препараты лития
Антигистаминные препараты
Сычёв Дмитрий Алексеевич
Findings
Остроумова Ольга Дмитриевна
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.